The potential mechanism may be that patients with low lymphocyte count may have reduced immune surveillance capacity to inhibit tumor cell growth or migration through either cytotoxic activity or cytokine production, or through high infiltration of tumor‐associated macrophages (TAMs) and high production of inflammatory cytokines (Interleukin [IL]‐6, IL‐8, IL‐17), which stimulate neutrophilia.31, 32, 33. The gene discussed is IL17A; the disease is neoplasm.